gila monster venom glp-1 monster: meet the lizard whose venomous bite is saving lives Gila monster: meet the lizard

Strive Compounding Pharmacy sues Eli Lilly and Novo Nordisk over alleged GLP-1 weight loss drug competition limits

According to the 2024 World Obesity Report, the global prevalence of obesity is steadily increasing, with projections indicating that by 2035, over half of the world's population will be classified as overweight [1]

As reported at the 2026 Crohns and Colitis Congress, GLP-1 RAs are potentially beneficial as an adjunct to Crohns disease management for patients with overweight or obesity.

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Data were analyzed narratively to elucidate potential mechanisms and translational relevance